PSI Named a 2025 Fierce CRO Award Finalist for Excellence in Clinical Trial Management

ZUG, Switzerland, 21 May 2025 – PSI has been named a finalist for the 2025 Fierce CRO Awards by Fierce Biotech in the category of Excellence in Clinical Trial Management, recognized for its leadership in managing complex radiopharmaceutical clinical trials and delivering high-impact pivotal studies.

At the heart of PSI’s submission is its pioneering work in radiopharmaceutical clinical trials, one of the most demanding frontiers in clinical research. PSI continues to lead the way by:

• Expanding a global network of trial sites with nuclear medicine and imaging capabilties
• Introducing dedicated roles in nuclear medicine, dosimetry, and diagnostic imaging
• Developing high-level and field-based radiopharma providing specialized, field-based training with radiation experts, radiologists and Scientific Advisory Board input
• Embedding operational strategies designed for precision, agility, and long-term scalability

This rigorous infrastructure has earned the trust of leading radiopharma companies, who repeatedly select PSI to run their pivotal trials and bring their first-in-class radioligand therapies (RLTs) to market — faster. 

“We’ve built a global team of clinical experts backed by the operational muscle and site relationships needed to make high-stakes nuclear medicine trials successful. When sponsors are racing against the clock, they need more than a CRO — they need a partner with deep expertise and zero tolerance for delay. Because in this work, every patient counts.”

Rhonda Critchlow, Head of Therapeutic Strategy at PSI  

The Fierce CRO Awards celebrate exceptional achievements and innovations by Contract Research Organizations (CROs). These awards honor CROs that have demonstrated outstanding performance, innovation, and leadership in delivering high-qualityresearch and development services. By recognizing the excellence of CROs, the awards aim to highlight the critical role they play in advancing life sciences research and improving patient outcomes.

The Fierce CRO Awards finalists were judged on: Innovation and Impact, Measurable Outcomes, Sustainability and Scalability and Ethical and Regulatory Adherence. Winners will be announced on June 18.

ENDS

 

About PSI  

PSI CRO is a global full-service contract research organization (CRO), committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors. PSI’s key operational differentiator is on-time delivery of clinical trials. This metric remained above 90% in 2024.  

The company specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, autoimmune, infectious diseases, neurology, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies.  

In 2025, PSI is celebrating its 30th year of business as the only fully independent and privately owned mid-sized CRO. PSI employs over 3,000 people across 56 countries as of December 31, 2024. Global headquarters are in Switzerland at 113a Baarerstrasse, Zug 6300. 

For more information, visit www.psi-cro.com. 

About Fierce Biotech 

Fierce Biotech is the biotech industry’s daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free here. 

For Media Inquiries 
Ashley Collins 
+1 919-972-9572 
ashley.stufanocollins@psi-cro.com